CLINICAL TRIAL: 0N01910NA WITH EITHER IRINOTEN OR OXALIPLATIN IN ADVANCED SOLID

临床试验：0N01910NA 与伊立替汀或奥沙利铂在高级固体中

• 批准号: 7953731
• 负责人: TAKAO OHNUMA
• 金额: $ 1.25万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-01 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7953731
• 关键词: Antineoplastic Agents; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Institution; Research; Research Personnel; Resources; Solid; Source; Therapeutic Effect; Toxic effect; United States National Institutes of Health; improved; irinotecan; oxaliplatin

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypothesis: Addition of an investigational agent ON 01910.Na to currently available anticancer agent, oxaliplatin or irinotecan improves therapeutic effects of oxaliplatin or irinotecan without added toxicity.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 假设： 在现有抗癌药物奥沙利铂或伊立替康的基础上加入研究药物01910.Na，可在不增加毒性的情况下提高奥沙利铂或伊立替康的疗效。